WO2005097182A1 - 経粘膜及び経皮投与を可能にする抗原薬物ヴィークル、これを用いる粘膜免疫の誘導方法、粘膜ワクチン及びdds - Google Patents
経粘膜及び経皮投与を可能にする抗原薬物ヴィークル、これを用いる粘膜免疫の誘導方法、粘膜ワクチン及びdds Download PDFInfo
- Publication number
- WO2005097182A1 WO2005097182A1 PCT/JP2005/005659 JP2005005659W WO2005097182A1 WO 2005097182 A1 WO2005097182 A1 WO 2005097182A1 JP 2005005659 W JP2005005659 W JP 2005005659W WO 2005097182 A1 WO2005097182 A1 WO 2005097182A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- vaccine
- mucosal
- antigen
- protein
- psf
- Prior art date
Links
- 229960005486 vaccine Drugs 0.000 title claims abstract description 101
- 230000036039 immunity Effects 0.000 title claims abstract description 49
- 239000003937 drug carrier Substances 0.000 title claims abstract description 35
- 238000000034 method Methods 0.000 title claims abstract description 29
- 230000001939 inductive effect Effects 0.000 title claims abstract description 20
- 239000000427 antigen Substances 0.000 claims abstract description 66
- 102000036639 antigens Human genes 0.000 claims abstract description 66
- 108091007433 antigens Proteins 0.000 claims abstract description 66
- 238000004519 manufacturing process Methods 0.000 claims abstract description 37
- 206010020751 Hypersensitivity Diseases 0.000 claims abstract description 11
- 230000007815 allergy Effects 0.000 claims abstract description 11
- 208000026935 allergic disease Diseases 0.000 claims abstract description 9
- 230000003449 preventive effect Effects 0.000 claims abstract description 5
- 102100030343 Antigen peptide transporter 2 Human genes 0.000 claims description 54
- 101000652582 Homo sapiens Antigen peptide transporter 2 Proteins 0.000 claims description 54
- 102100032617 Pulmonary surfactant-associated protein B Human genes 0.000 claims description 48
- 239000012634 fragment Substances 0.000 claims description 48
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 48
- 206010022000 influenza Diseases 0.000 claims description 37
- 239000003580 lung surfactant Substances 0.000 claims description 34
- 150000002632 lipids Chemical class 0.000 claims description 33
- 239000003814 drug Substances 0.000 claims description 27
- 210000003928 nasal cavity Anatomy 0.000 claims description 25
- 241000700605 Viruses Species 0.000 claims description 22
- 229940079593 drug Drugs 0.000 claims description 18
- 108090000623 proteins and genes Proteins 0.000 claims description 16
- 230000006698 induction Effects 0.000 claims description 15
- 102000004169 proteins and genes Human genes 0.000 claims description 15
- 239000012528 membrane Substances 0.000 claims description 14
- 210000004877 mucosa Anatomy 0.000 claims description 14
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 13
- 101001086862 Homo sapiens Pulmonary surfactant-associated protein B Proteins 0.000 claims description 9
- AWUCVROLDVIAJX-UHFFFAOYSA-N glycerol 1-phosphate Chemical compound OCC(O)COP(O)(O)=O AWUCVROLDVIAJX-UHFFFAOYSA-N 0.000 claims description 9
- 229960000856 protein c Drugs 0.000 claims description 9
- 239000002253 acid Substances 0.000 claims description 8
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 claims description 8
- 102000004127 Cytokines Human genes 0.000 claims description 7
- 108090000695 Cytokines Proteins 0.000 claims description 7
- 102000000528 Pulmonary Surfactant-Associated Proteins Human genes 0.000 claims description 7
- 108010041520 Pulmonary Surfactant-Associated Proteins Proteins 0.000 claims description 7
- ATBOMIWRCZXYSZ-XZBBILGWSA-N [1-[2,3-dihydroxypropoxy(hydroxy)phosphoryl]oxy-3-hexadecanoyloxypropan-2-yl] (9e,12e)-octadeca-9,12-dienoate Chemical compound CCCCCCCCCCCCCCCC(=O)OCC(COP(O)(=O)OCC(O)CO)OC(=O)CCCCCCC\C=C\C\C=C\CCCCC ATBOMIWRCZXYSZ-XZBBILGWSA-N 0.000 claims description 7
- 230000016784 immunoglobulin production Effects 0.000 claims description 7
- TZCPCKNHXULUIY-RGULYWFUSA-N 1,2-distearoyl-sn-glycero-3-phosphoserine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@H](N)C(O)=O)OC(=O)CCCCCCCCCCCCCCCCC TZCPCKNHXULUIY-RGULYWFUSA-N 0.000 claims description 6
- ZWZWYGMENQVNFU-UHFFFAOYSA-N Glycerophosphorylserin Natural products OC(=O)C(N)COP(O)(=O)OCC(O)CO ZWZWYGMENQVNFU-UHFFFAOYSA-N 0.000 claims description 6
- 108010042653 IgA receptor Proteins 0.000 claims description 6
- 102100034014 Prolyl 3-hydroxylase 3 Human genes 0.000 claims description 6
- 101800004937 Protein C Proteins 0.000 claims description 6
- 102100036546 Salivary acidic proline-rich phosphoprotein 1/2 Human genes 0.000 claims description 6
- 101800001700 Saposin-D Proteins 0.000 claims description 6
- 230000002209 hydrophobic effect Effects 0.000 claims description 6
- 210000002345 respiratory system Anatomy 0.000 claims description 6
- 229940124597 therapeutic agent Drugs 0.000 claims description 6
- KILNVBDSWZSGLL-KXQOOQHDSA-N 1,2-dihexadecanoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCC KILNVBDSWZSGLL-KXQOOQHDSA-N 0.000 claims description 5
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 claims description 5
- 235000021314 Palmitic acid Nutrition 0.000 claims description 4
- 108010007125 Pulmonary Surfactant-Associated Protein C Proteins 0.000 claims description 4
- 102000007620 Pulmonary Surfactant-Associated Protein C Human genes 0.000 claims description 4
- 239000013566 allergen Substances 0.000 claims description 4
- WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 claims description 4
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 claims description 3
- BVKFQEAERCHBTG-UHFFFAOYSA-N 17,18,19-trihydroxypentatriacontane-16,20-dione Chemical compound CCCCCCCCCCCCCCCC(=O)C(O)C(O)C(O)C(=O)CCCCCCCCCCCCCCC BVKFQEAERCHBTG-UHFFFAOYSA-N 0.000 claims description 3
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 claims description 3
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 claims description 3
- JZNWSCPGTDBMEW-UHFFFAOYSA-N Glycerophosphorylethanolamin Natural products NCCOP(O)(=O)OCC(O)CO JZNWSCPGTDBMEW-UHFFFAOYSA-N 0.000 claims description 3
- 239000005642 Oleic acid Substances 0.000 claims description 3
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 claims description 3
- 235000021355 Stearic acid Nutrition 0.000 claims description 3
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 claims description 3
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 claims description 3
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 claims description 3
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 claims description 3
- 150000008104 phosphatidylethanolamines Chemical class 0.000 claims description 3
- 239000008117 stearic acid Substances 0.000 claims description 3
- 239000003795 chemical substances by application Substances 0.000 claims description 2
- 235000021313 oleic acid Nutrition 0.000 claims description 2
- 150000003905 phosphatidylinositols Chemical class 0.000 claims description 2
- YHHSONZFOIEMCP-UHFFFAOYSA-O phosphocholine Chemical compound C[N+](C)(C)CCOP(O)(O)=O YHHSONZFOIEMCP-UHFFFAOYSA-O 0.000 claims description 2
- 230000000069 prophylactic effect Effects 0.000 claims description 2
- 125000003275 alpha amino acid group Chemical group 0.000 claims 2
- 239000000356 contaminant Substances 0.000 claims 1
- 125000003473 lipid group Chemical group 0.000 claims 1
- 235000010987 pectin Nutrition 0.000 claims 1
- 229920001277 pectin Polymers 0.000 claims 1
- 239000001814 pectin Substances 0.000 claims 1
- 239000003981 vehicle Substances 0.000 abstract description 43
- 230000003248 secreting effect Effects 0.000 abstract description 6
- 230000000699 topical effect Effects 0.000 abstract 1
- 230000000694 effects Effects 0.000 description 53
- 150000001413 amino acids Chemical class 0.000 description 48
- 108010007131 Pulmonary Surfactant-Associated Protein B Proteins 0.000 description 43
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 43
- 239000002953 phosphate buffered saline Substances 0.000 description 43
- 230000003053 immunization Effects 0.000 description 41
- 238000002649 immunization Methods 0.000 description 41
- 229960003971 influenza vaccine Drugs 0.000 description 41
- 239000000243 solution Substances 0.000 description 40
- 241000699670 Mus sp. Species 0.000 description 29
- 238000002360 preparation method Methods 0.000 description 27
- 239000002671 adjuvant Substances 0.000 description 25
- 208000015181 infectious disease Diseases 0.000 description 23
- 210000004072 lung Anatomy 0.000 description 23
- 102000004196 processed proteins & peptides Human genes 0.000 description 22
- 210000004369 blood Anatomy 0.000 description 20
- 239000008280 blood Substances 0.000 description 20
- 210000004027 cell Anatomy 0.000 description 20
- 239000012530 fluid Substances 0.000 description 19
- NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 16
- 238000010254 subcutaneous injection Methods 0.000 description 16
- 239000007929 subcutaneous injection Substances 0.000 description 16
- 239000000126 substance Substances 0.000 description 16
- 150000003904 phospholipids Chemical class 0.000 description 15
- 229920001184 polypeptide Polymers 0.000 description 15
- 238000005406 washing Methods 0.000 description 14
- 230000001965 increasing effect Effects 0.000 description 13
- 235000018102 proteins Nutrition 0.000 description 13
- 210000002966 serum Anatomy 0.000 description 13
- 210000004443 dendritic cell Anatomy 0.000 description 12
- 210000004379 membrane Anatomy 0.000 description 12
- 238000011161 development Methods 0.000 description 11
- 230000018109 developmental process Effects 0.000 description 11
- 229940031551 inactivated vaccine Drugs 0.000 description 11
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 10
- 229940066294 lung surfactant Drugs 0.000 description 10
- 241000699666 Mus <mouse, genus> Species 0.000 description 9
- 108010007100 Pulmonary Surfactant-Associated Protein A Proteins 0.000 description 9
- 102100027773 Pulmonary surfactant-associated protein A2 Human genes 0.000 description 9
- 239000000203 mixture Substances 0.000 description 9
- 210000001331 nose Anatomy 0.000 description 9
- 210000000952 spleen Anatomy 0.000 description 9
- 238000007920 subcutaneous administration Methods 0.000 description 9
- 241000712461 unidentified influenza virus Species 0.000 description 9
- 239000004480 active ingredient Substances 0.000 description 8
- 230000028993 immune response Effects 0.000 description 8
- 210000004400 mucous membrane Anatomy 0.000 description 8
- 238000011002 quantification Methods 0.000 description 8
- 239000000725 suspension Substances 0.000 description 8
- 230000028327 secretion Effects 0.000 description 7
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 description 6
- 101150013553 CD40 gene Proteins 0.000 description 6
- 108010049048 Cholera Toxin Proteins 0.000 description 6
- 102000009016 Cholera Toxin Human genes 0.000 description 6
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 6
- 241001465754 Metazoa Species 0.000 description 6
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 6
- 208000013616 Respiratory Distress Syndrome Diseases 0.000 description 6
- 102100040245 Tumor necrosis factor receptor superfamily member 5 Human genes 0.000 description 6
- 210000000612 antigen-presenting cell Anatomy 0.000 description 6
- 235000014113 dietary fatty acids Nutrition 0.000 description 6
- 229930195729 fatty acid Natural products 0.000 description 6
- 239000000194 fatty acid Substances 0.000 description 6
- 150000004665 fatty acids Chemical class 0.000 description 6
- 238000011081 inoculation Methods 0.000 description 6
- 239000002689 soil Substances 0.000 description 6
- 239000004094 surface-active agent Substances 0.000 description 6
- 230000009385 viral infection Effects 0.000 description 6
- 108020004414 DNA Proteins 0.000 description 5
- 238000012286 ELISA Assay Methods 0.000 description 5
- 241000282412 Homo Species 0.000 description 5
- 101000612671 Homo sapiens Pulmonary surfactant-associated protein C Proteins 0.000 description 5
- 238000006243 chemical reaction Methods 0.000 description 5
- 230000003292 diminished effect Effects 0.000 description 5
- 230000002708 enhancing effect Effects 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 230000012010 growth Effects 0.000 description 5
- 230000002434 immunopotentiative effect Effects 0.000 description 5
- 239000007788 liquid Substances 0.000 description 5
- 210000004698 lymphocyte Anatomy 0.000 description 5
- 239000011780 sodium chloride Substances 0.000 description 5
- 210000003437 trachea Anatomy 0.000 description 5
- 238000002255 vaccination Methods 0.000 description 5
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 4
- 206010061218 Inflammation Diseases 0.000 description 4
- 102000004388 Interleukin-4 Human genes 0.000 description 4
- 108090000978 Interleukin-4 Proteins 0.000 description 4
- 108091005804 Peptidases Proteins 0.000 description 4
- 238000000692 Student's t-test Methods 0.000 description 4
- 238000001042 affinity chromatography Methods 0.000 description 4
- 210000003719 b-lymphocyte Anatomy 0.000 description 4
- 239000000872 buffer Substances 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- 230000036541 health Effects 0.000 description 4
- 230000004727 humoral immunity Effects 0.000 description 4
- 230000004054 inflammatory process Effects 0.000 description 4
- 235000000346 sugar Nutrition 0.000 description 4
- 238000012353 t test Methods 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 241000238631 Hexapoda Species 0.000 description 3
- 102000043131 MHC class II family Human genes 0.000 description 3
- 108091054438 MHC class II family Proteins 0.000 description 3
- 229920001213 Polysorbate 20 Polymers 0.000 description 3
- 229920002684 Sepharose Polymers 0.000 description 3
- 238000002835 absorbance Methods 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 230000004913 activation Effects 0.000 description 3
- 238000012512 characterization method Methods 0.000 description 3
- 229940028617 conventional vaccine Drugs 0.000 description 3
- 238000011156 evaluation Methods 0.000 description 3
- 210000001035 gastrointestinal tract Anatomy 0.000 description 3
- 230000002779 inactivation Effects 0.000 description 3
- 210000002540 macrophage Anatomy 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 3
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 3
- 230000002265 prevention Effects 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 238000006467 substitution reaction Methods 0.000 description 3
- 230000009885 systemic effect Effects 0.000 description 3
- PORPENFLTBBHSG-MGBGTMOVSA-N 1,2-dihexadecanoyl-sn-glycerol-3-phosphate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(O)=O)OC(=O)CCCCCCCCCCCCCCC PORPENFLTBBHSG-MGBGTMOVSA-N 0.000 description 2
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- 241000283707 Capra Species 0.000 description 2
- 108091026890 Coding region Proteins 0.000 description 2
- 102000029816 Collagenase Human genes 0.000 description 2
- 108060005980 Collagenase Proteins 0.000 description 2
- 108010041986 DNA Vaccines Proteins 0.000 description 2
- 229940021995 DNA vaccine Drugs 0.000 description 2
- 108010012253 E coli heat-labile enterotoxin Proteins 0.000 description 2
- 238000008157 ELISA kit Methods 0.000 description 2
- 241000287828 Gallus gallus Species 0.000 description 2
- 102000018713 Histocompatibility Antigens Class II Human genes 0.000 description 2
- 108010027412 Histocompatibility Antigens Class II Proteins 0.000 description 2
- 241000371980 Influenza B virus (B/Shanghai/361/2002) Species 0.000 description 2
- 108090001005 Interleukin-6 Proteins 0.000 description 2
- 241000711408 Murine respirovirus Species 0.000 description 2
- 102000035195 Peptidases Human genes 0.000 description 2
- 239000004365 Protease Substances 0.000 description 2
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 2
- 210000001744 T-lymphocyte Anatomy 0.000 description 2
- 102000004887 Transforming Growth Factor beta Human genes 0.000 description 2
- 108090001012 Transforming Growth Factor beta Proteins 0.000 description 2
- 239000007983 Tris buffer Substances 0.000 description 2
- 208000036142 Viral infection Diseases 0.000 description 2
- VEZXCJBBBCKRPI-UHFFFAOYSA-N beta-propiolactone Chemical compound O=C1CCO1 VEZXCJBBBCKRPI-UHFFFAOYSA-N 0.000 description 2
- 238000009739 binding Methods 0.000 description 2
- 230000000903 blocking effect Effects 0.000 description 2
- 229960002424 collagenase Drugs 0.000 description 2
- ATDGTVJJHBUTRL-UHFFFAOYSA-N cyanogen bromide Chemical group BrC#N ATDGTVJJHBUTRL-UHFFFAOYSA-N 0.000 description 2
- 238000000586 desensitisation Methods 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- POULHZVOKOAJMA-UHFFFAOYSA-N dodecanoic acid Chemical compound CCCCCCCCCCCC(O)=O POULHZVOKOAJMA-UHFFFAOYSA-N 0.000 description 2
- 125000003438 dodecyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 2
- 235000013601 eggs Nutrition 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 230000007613 environmental effect Effects 0.000 description 2
- 210000003743 erythrocyte Anatomy 0.000 description 2
- 238000000684 flow cytometry Methods 0.000 description 2
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 238000010353 genetic engineering Methods 0.000 description 2
- 102000047087 human SFTPC Human genes 0.000 description 2
- 229940099472 immunoglobulin a Drugs 0.000 description 2
- 239000000568 immunological adjuvant Substances 0.000 description 2
- 229940026289 infasurf Drugs 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 239000003446 ligand Substances 0.000 description 2
- 230000014759 maintenance of location Effects 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 210000002850 nasal mucosa Anatomy 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- 238000010647 peptide synthesis reaction Methods 0.000 description 2
- 102000013415 peroxidase activity proteins Human genes 0.000 description 2
- 108040007629 peroxidase activity proteins Proteins 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 229960000380 propiolactone Drugs 0.000 description 2
- 235000004252 protein component Nutrition 0.000 description 2
- 229940024999 proteolytic enzymes for treatment of wounds and ulcers Drugs 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 238000001228 spectrum Methods 0.000 description 2
- 239000011550 stock solution Substances 0.000 description 2
- 238000013268 sustained release Methods 0.000 description 2
- 239000012730 sustained-release form Substances 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 description 2
- 239000003053 toxin Substances 0.000 description 2
- 231100000765 toxin Toxicity 0.000 description 2
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 2
- 230000003612 virological effect Effects 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- BIABMEZBCHDPBV-MPQUPPDSSA-N 1,2-palmitoyl-sn-glycero-3-phospho-(1'-sn-glycerol) Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@@H](O)CO)OC(=O)CCCCCCCCCCCCCCC BIABMEZBCHDPBV-MPQUPPDSSA-N 0.000 description 1
- JWDYCNIAQWPBHD-UHFFFAOYSA-N 1-(2-methylphenyl)glycerol Chemical compound CC1=CC=CC=C1OCC(O)CO JWDYCNIAQWPBHD-UHFFFAOYSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- 208000030507 AIDS Diseases 0.000 description 1
- 241000238876 Acari Species 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- 206010001881 Alveolar proteinosis Diseases 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- OISWSORSLQOGFV-AVGNSLFASA-N Arg-Met-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@H](CCSC)NC(=O)[C@@H](N)CCCN=C(N)N OISWSORSLQOGFV-AVGNSLFASA-N 0.000 description 1
- 238000000035 BCA protein assay Methods 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 101150047495 CTB5 gene Proteins 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 1
- 241000700199 Cavia porcellus Species 0.000 description 1
- 241000218645 Cedrus Species 0.000 description 1
- 241000283153 Cetacea Species 0.000 description 1
- 241000251730 Chondrichthyes Species 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 241001125840 Coryphaenidae Species 0.000 description 1
- 206010011732 Cyst Diseases 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 101000867232 Escherichia coli Heat-stable enterotoxin II Proteins 0.000 description 1
- 229920001503 Glucan Polymers 0.000 description 1
- 208000005176 Hepatitis C Diseases 0.000 description 1
- 208000019758 Hypergammaglobulinemia Diseases 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 241001500351 Influenzavirus A Species 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- 108010002616 Interleukin-5 Proteins 0.000 description 1
- 206010022678 Intestinal infections Diseases 0.000 description 1
- 239000005639 Lauric acid Substances 0.000 description 1
- CLVUXCBGKUECIT-HJGDQZAQSA-N Leu-Asp-Thr Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O CLVUXCBGKUECIT-HJGDQZAQSA-N 0.000 description 1
- YOKVEHGYYQEQOP-QWRGUYRKSA-N Leu-Leu-Gly Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)NCC(O)=O YOKVEHGYYQEQOP-QWRGUYRKSA-N 0.000 description 1
- HLFSDGLLUJUHTE-SNVBAGLBSA-N Levamisole Chemical compound C1([C@H]2CN3CCSC3=N2)=CC=CC=C1 HLFSDGLLUJUHTE-SNVBAGLBSA-N 0.000 description 1
- NPBGTPKLVJEOBE-IUCAKERBSA-N Lys-Arg Chemical compound NCCCC[C@H](N)C(=O)N[C@H](C(O)=O)CCCNC(N)=N NPBGTPKLVJEOBE-IUCAKERBSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 201000005505 Measles Diseases 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- 102000018697 Membrane Proteins Human genes 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 241000187479 Mycobacterium tuberculosis Species 0.000 description 1
- 229920002274 Nalgene Polymers 0.000 description 1
- 102000005348 Neuraminidase Human genes 0.000 description 1
- 108010006232 Neuraminidase Proteins 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- 241000283203 Otariidae Species 0.000 description 1
- 108010081690 Pertussis Toxin Proteins 0.000 description 1
- 241000287463 Phalacrocorax Species 0.000 description 1
- 208000000474 Poliomyelitis Diseases 0.000 description 1
- 241000220259 Raphanus Species 0.000 description 1
- 235000006140 Raphanus sativus var sativus Nutrition 0.000 description 1
- 206010057190 Respiratory tract infections Diseases 0.000 description 1
- -1 SEQ ID NO: 2 amino acids Chemical class 0.000 description 1
- 108010071390 Serum Albumin Proteins 0.000 description 1
- 102000007562 Serum Albumin Human genes 0.000 description 1
- 201000003176 Severe Acute Respiratory Syndrome Diseases 0.000 description 1
- 108010017898 Shiga Toxins Proteins 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 241000700618 Vaccinia virus Species 0.000 description 1
- 241000607479 Yersinia pestis Species 0.000 description 1
- 241001211763 Yukara Species 0.000 description 1
- 241001599774 Zilla <spider> Species 0.000 description 1
- 239000008186 active pharmaceutical agent Substances 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000000240 adjuvant effect Effects 0.000 description 1
- 239000003905 agrochemical Substances 0.000 description 1
- ILRRQNADMUWWFW-UHFFFAOYSA-K aluminium phosphate Chemical compound O1[Al]2OP1(=O)O2 ILRRQNADMUWWFW-UHFFFAOYSA-K 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 230000030741 antigen processing and presentation Effects 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 230000027455 binding Effects 0.000 description 1
- 239000012148 binding buffer Substances 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000000233 bronchiolar non-ciliated Anatomy 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910001424 calcium ion Inorganic materials 0.000 description 1
- 102000023852 carbohydrate binding proteins Human genes 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 208000031513 cyst Diseases 0.000 description 1
- 230000007123 defense Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- LHCZDUCPSRJDJT-UHFFFAOYSA-N dilauroyl phosphatidylglycerol Chemical compound CCCCCCCCCCCC(=O)OCC(COP(O)(=O)OCC(O)CO)OC(=O)CCCCCCCCCCC LHCZDUCPSRJDJT-UHFFFAOYSA-N 0.000 description 1
- 229960005160 dimyristoylphosphatidylglycerol Drugs 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- ZGSPNIOCEDOHGS-UHFFFAOYSA-L disodium [3-[2,3-di(octadeca-9,12-dienoyloxy)propoxy-oxidophosphoryl]oxy-2-hydroxypropyl] 2,3-di(octadeca-9,12-dienoyloxy)propyl phosphate Chemical compound [Na+].[Na+].CCCCCC=CCC=CCCCCCCCC(=O)OCC(OC(=O)CCCCCCCC=CCC=CCCCCC)COP([O-])(=O)OCC(O)COP([O-])(=O)OCC(OC(=O)CCCCCCCC=CCC=CCCCCC)COC(=O)CCCCCCCC=CCC=CCCCCC ZGSPNIOCEDOHGS-UHFFFAOYSA-L 0.000 description 1
- BPHQZTVXXXJVHI-AJQTZOPKSA-N ditetradecanoyl phosphatidylglycerol Chemical compound CCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@@H](O)CO)OC(=O)CCCCCCCCCCCCC BPHQZTVXXXJVHI-AJQTZOPKSA-N 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 229940088679 drug related substance Drugs 0.000 description 1
- 239000002158 endotoxin Substances 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000012894 fetal calf serum Substances 0.000 description 1
- 208000010824 fish disease Diseases 0.000 description 1
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 1
- 235000021588 free fatty acids Nutrition 0.000 description 1
- 235000013376 functional food Nutrition 0.000 description 1
- 230000005021 gait Effects 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 239000007973 glycine-HCl buffer Substances 0.000 description 1
- 230000009422 growth inhibiting effect Effects 0.000 description 1
- 230000009931 harmful effect Effects 0.000 description 1
- 238000011597 hartley guinea pig Methods 0.000 description 1
- 235000013402 health food Nutrition 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 229940027941 immunoglobulin g Drugs 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 108010019701 influenza virus M-protein Proteins 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 229940028885 interleukin-4 Drugs 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 239000000644 isotonic solution Substances 0.000 description 1
- 238000002350 laparotomy Methods 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 230000000503 lectinlike effect Effects 0.000 description 1
- 229960001614 levamisole Drugs 0.000 description 1
- 230000004576 lipid-binding Effects 0.000 description 1
- 229940124590 live attenuated vaccine Drugs 0.000 description 1
- 229940023012 live-attenuated vaccine Drugs 0.000 description 1
- 230000004807 localization Effects 0.000 description 1
- 210000005174 lung dendritic cell Anatomy 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 230000034217 membrane fusion Effects 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 239000003607 modifier Substances 0.000 description 1
- 230000016379 mucosal immune response Effects 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 230000000474 nursing effect Effects 0.000 description 1
- 229960005030 other vaccine in atc Drugs 0.000 description 1
- 230000036407 pain Effects 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 235000020030 perry Nutrition 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 229940127557 pharmaceutical product Drugs 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 125000001095 phosphatidyl group Chemical group 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 230000004853 protein function Effects 0.000 description 1
- 230000002797 proteolythic effect Effects 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 210000003705 ribosome Anatomy 0.000 description 1
- 201000005404 rubella Diseases 0.000 description 1
- 108010038196 saccharide-binding proteins Proteins 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 230000035807 sensation Effects 0.000 description 1
- 239000012679 serum free medium Substances 0.000 description 1
- 238000007086 side reaction Methods 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- TUNFSRHWOTWDNC-HKGQFRNVSA-N tetradecanoic acid Chemical compound CCCCCCCCCCCCC[14C](O)=O TUNFSRHWOTWDNC-HKGQFRNVSA-N 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 238000013271 transdermal drug delivery Methods 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- 238000002604 ultrasonography Methods 0.000 description 1
- 229940126580 vector vaccine Drugs 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 239000013603 viral vector Substances 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
- A61K2039/541—Mucosal route
Definitions
- An antigen drug vehicle that enables transmucosal and transdermal administration, a method for inducing mucosal immunity using the same, a mucosal vaccine and DDS
- the present invention relates to an antigen drug vehicle that enables transmucosal administration and transdermal administration, and more particularly, to an antigen-specific secretion characterized by using the vehicle for a desired antigen or drug.
- the present invention relates to a method for inducing mucosal immunity to produce type I immunoglobulin A preferentially and effectively, particularly selectively, to a mucosal vaccine, to prevention and treatment of allergy, and to a drug delivery system.
- the natural route of infection such as bacteria and viruses is mucous membranes such as the nasal cavity, trachea, and intestinal tract, and is different from the above route. It is desired to achieve infection protection by an inoculation route in accordance with the actual state of natural infection, and particularly to infection protection on the mucous membrane by administering the vaccine via the mucosa.
- immunoglobulin G (hereinafter abbreviated as “IgG” or “IgG antibody”) is mainly produced in the blood to induce humoral immunity.
- immunoglobulin A (hereinafter abbreviated as “IgA” or “I g A antibody”) responsible for mucosal immunity is not generated almost produced, the establishment of mucosal immunity is not expected. Need for IgA antibody Sex and efficacy are as follows: IgA antibodies protect against infection of the respiratory tract, such as the nasal cavity and trachea, by droplets and air, and protection of the mucous membrane, which is the gateway to oral intestinal infection. It is responsible for mucosal immunity and plays a very important role in clinical immunity.
- IgG antibodies have high specificity for antigens, have a narrow spectrum of protection against infection, and are almost ineffective in protecting against infection with antigenic mutant pathogens, whereas IgA antibodies have cross-immunity, that is, Cross-neutralizing activity broadens the spectrum of infection protection and protects against infection against mutant antigens.
- the IgG antibody titer in the blood is determined by one or more additional inoculations, so-called booster inoculations, based on the subsequent IgG antibody retention status. Need to be increased. For this reason, the cost and labor are repeatedly required, and the effect is recognized in the elderly, adults and school children who have been blessed with the opportunity for booster vaccination, but it is ineffective for younger children who tend to miss the opportunity, especially for infants under 2 years old Cases are scattered.
- the optimal temperature for growth is 25, and in 39, a method of inoculating a cold-adapted influenza virus strain that rarely grows into the nasal cavity has been put into practical use.However, the mechanism of attenuating the cold-adapted parent strain is not clear, and there is a risk of toxicity return. Sex cannot be denied.
- the active ingredient of the vaccine is a live virus, it has a high level of invasion into cells and is excellent in initializing immunity.However, mild influenza symptoms are sporadic, so infections with influenza are likely to be severe. Disadvantages such as being unusable for high-risk humans and elderly people are seen.
- Immune adjuvant is a general term for substances that have regulatory activities such as strengthening or suppressing the immune response, and substances related to the administration form for the purpose of sustained release and storage of antigens in the inoculated body, and the enhancement of the immune response. Substances for the purpose of control and control. Among them, vaccines and toxoids using, for example, aluminum phosphate, myopan, etc. have already been put into practical use as adjuvants for the former, administration form. However, the practical use of adjuvants to enhance and enhance the immune response has not yet been known.
- live bacteria-derived BCG, BCG-CWS, endotoxin, glucan, etc. synthesized MDP, levamisole, poly I-poly C, vessutin, etc., and cytokines interferon, TNF, CSF
- MDP levamisole
- poly I-poly C poly I-poly C
- vessutin etc.
- cytokines interferon, TNF, CSF
- Patent Document 2 pertussis toxin B oligomer
- cholera toxin (patent document 3), heat-labile enterotoxin B subunit LTB of Escherichia coli (patent document 4), starch particles (patent document 5), cholera toxin B chain protein CTB (patent document 5)
- Patent Document 6 B subunit of verotoxin 1 (Patent Document 7), oligonucleotide (Patent Document 8), Inuichi Leukin 12 (Non-Patent Document 1), etc. It has not been put to practical use.
- Patent Document 2 JP-A-3-135923
- Patent Document 3 Japanese Patent Publication No. 10-500102
- Patent Document 4 Japanese Translation of PCT International Publication No. 2001-523729
- Patent Document 5 Japanese Patent Application Publication No. 2002-50452
- Patent Document 6 JP-A-2003-116385
- Patent Document 7 JP-A-2003-50452
- Patent Document 8 PCT publication WO 00/20039 pamphlet
- Non-patent document 1 Infection and Immunity ⁇ Vol. 71, pp. 4780-4788, 2003
- Non-patent document 2 Journal of neonatal Nursing, Vol. 10, pp. 2--11, 2004
- Non-patent document 3 Biology of the Neonate Volume 74 (suppl 1), pp. 9-14, 1998
- Non-Patent Document 4 American Journal of Respiratory Cell and Molecular Biology, Vol. 24, pp. 452-458, 2001
- the present application has the following objects. That is, the conventional inactivated vaccines and toxoids, confers the ability to induce the production, local immunity or mucosal immunity of I g A antibody. Development of safe and effective technology for that. Conversion of conventional humoral immune vaccine to safe and effective mucosal immune vaccine. Also, prevent and treat allergies, and establish a transmucosal and transdermal drug delivery system (hereinafter abbreviated as “DDS”) that administers and transports drugs via mucous membranes and skin.
- DDS transmucosal and transdermal drug delivery system
- the present invention provides an antigen-drug vehicle that enables transmucosal administration and transdermal administration, and an antigen-specific secretory immunoglobulin characterized by using the vehicle for a desired antigen or drug. It is intended to provide a method for exposing mucosal immunity, a mucosal vaccine, a prophylactic and therapeutic agent for allergy, and a transmucosal / transdermal DDS, in which A is preferentially and effectively produced, particularly selectively.
- Application and use of the antigen drug vehicle provided by the present invention will realize and spread mucosal vaccines for all kinds of infectious diseases, preventive and therapeutic agents for allergy, and transmucosal and transdermal DDS.
- Mucosal vaccines are an immunization tool that is suited to the actual situation of natural infections, and therefore offer significantly better infection protection than conventional vaccines.
- the nasal mucosa ig A induced by the drug substance vehicle induces inactivation of allergens there and enables desensitization.
- the application of the DDS to a wide variety of drugs enhances and promotes the preventive and therapeutic effects of transmucosal and transdermal drug administration. As a result, this invention will greatly improve the health, health and hygiene of all humankind, and will be the long-awaited gospel for medical, health and health workers in the world.
- FIG. 1 shows influenza virus infection in the nasal cavity (a), lunar cyst (b), and nasal cavity (c) and subalveolar alveoli (d) after administration of various nasal influenza vaccines. Suppression ! effect. * Indicates the level of significance (p ⁇ 0.01) between the administration group and the vaccine alone (no AD vehicle or adjuvant) by t-test (Example 1)
- Figure 2 shows nasal administration (a), subcutaneous injection (b) Anti-influenza antibody-producing IgA and IgG levels in nasal washes from influenza vaccine White bars indicate IgA levels, black bars indicate IgG levels (Example 2)
- FIG. 1 shows influenza virus infection in the nasal cavity (a), lunar cyst (b), and nasal cavity (c) and subalveolar alveoli (d) after administration of various nasal influenza vaccines. Suppression ! effect. * Indicates the level of significance (p ⁇ 0.01) between the administration group and the vaccine alone (no AD vehicle or adjuvant) by t-test (Example 1)
- FIG. 3 shows the effect of the adjuvant on the production of anti-influenza-specific antibodies IgA and IgG in lung washings by nasal (a) and subcutaneous injection (b) influenza vaccine administration.
- FIG. 4 shows the effects of PSF-2 and CTB on the production of anti-influenza-specific antibodies in blood by nasal (a) and subcutaneous injection (b) influenza vaccine administration.
- FIG. 5 shows the effect of PSF-2 and CTB on the secretion level of TGF- ⁇ in the nasal cavity (a) and alveolar (b) mucosa by administration of a nasal influenza vaccine.
- FIG. 6 shows the effect of the adjuvant on the production of anti-influenza-specific antibodies IgA and IgG in lung washings by nasal (a) and subcutaneous injection (b) influenza vaccine administration.
- FIG. 6 shows the effects of PSF-2 and CTB on the production of anti-influenza-specific antibodies in the nasal cavity (a), alveoli (b) and in serum (c) by the nasal influenza vaccine.
- Figure 7 shows the effect of SPF-2 and CTB on various cytokins secreted from nasal, lung and spleen lymphocytes by nasal influenza vaccine administration.
- Example 8 shows the effect of PSF-3 on the production of anti-influenza-specific antibodies in the nasal cavity (a), alveoli (b) and blood (c) by the nasal influenza vaccine.
- Example 9 BEST MODE FOR CARRYING OUT THE INVENTION
- Antigen drug vehicle The vehicle (Antigen and Drug Vehicle, hereinafter abbreviated as “AD vehicle” or “ADV”) is a lipid designed to enable transmucosal and transdermal administration of antigens and drugs. It is a complex of a protein and a protein.
- the AD vehicle consists of the following (a) to (c).
- Pulmonary surfactant protein B or a fragment thereof (not only natural fragments obtained by proteolytic enzymes, but also artificial fragments obtained by genetic engineering or peptide synthesis; Including substituted and / or deleted mutant fragments, etc.).
- pulmonary surfactant protein C or a fragment thereof (not only a natural fragment obtained by proteolytic enzymes, but also an artificial fragment obtained by genetic engineering or peptide synthesis, and substitution or substitution of one or more amino acids constituting such a fragment) And / or missing mutant fragments).
- Lipids such as phospholipids and fatty acids. Its shape is a membrane (spike-like or rolling-like lipid membrane) that has a spike-like or spike-like polypeptide chain on its surface, and the ends of the hydrophobic regions of a plurality of polypeptide chains are inserted into the lipid membrane and spiked. It is different from conventional lipid vesicles (ribosomes).
- the vehicle is a vehicle that enables transmucosal and transdermal administration of antigens and drugs.
- the components of the AD vehicle, the proteins, polypeptides or peptides and lipids used in the preparation and production of the vehicle, ie, lung surfactant proteins B and C, fragments thereof, and at least one of these fragment peptides The details of amino acid-substituted and / or deleted mutant fragments, and lipids such as phospholipids and fatty acids will be described later.
- Pulmonary surfactant Pulmonary surfactant has been put into practical use for the treatment of respiratory distress syndrome (RDS) since the mid-1990s, and a variety of pharmaceutical products derived from humans, humans, busines, etc.
- Non-Patent Document 2 Synthetic peptide preparations containing an active domain related to RDS treatment are also commercially available, and the design development and synthesis of SP-B and SP-C analogs are also in progress.
- the composition and composition of the pulmonary surfactant is as follows: about 90% lipids (phosphatichosercholine 67.3%, phosphatidylglycerol 19.3%, phosphatidylserine 3.2%, other free fatty acids, etc.) and about 10% protein (surfactant) (Hereinafter, abbreviated as “SP-A”, “SP-B”, “SP-C”, and “SP-D”).
- the molecular weights are 28-36 kDa for SP-A ifi, 15 kDa for B, 3.5 kDa for C, and 43 kDa for D.
- SP-A and D are hydrophilic (water-soluble) and lectin-like (membrane associated).
- SP-B and C are hydrophobic (lipid-soluble) and lipid-binding, have the ability to fit into phospholipid membranes, and have a surfactant effect.
- Pulmonary surfactant protein genes derived from humans, pests, bushus, etc. are known, for example, the human SP-B gene in GenBank / NCBI (htt // ww.ncbi.nlm.nih.gov.
- SEQ ID NO: 2 Human SP-B full-length amino acid sequence decoded from SEQ ID NO: 1;
- SEQ ID NO: 3 CDR base sequence of human SP-C gene DNA;
- SEQ ID NO: 4 Human SP-C full-length amino acid sequence decoded from SEQ ID NO: 3;
- SEQ ID NO: 5 CDR base sequence of SP-C1 occupying on human SP-C gene DNA; and
- SEQ ID NO: 6 SEQ ID NO: 5 Human SP-C1 full-length amino acid sequence decoded from.
- the preparation and production of the antigen drug vehicle according to the present invention is based on mammals such as humans, sea lions, bush, zilla, iruka, etc., and fish such as tuna, sharks, rays and possibly.
- mammals such as humans, sea lions, bush, zilla, iruka, etc.
- fish such as tuna, sharks, rays and peer.
- the conventional combination of SP-B and SP-C and the combination of SP-B and SP-C1 can be used.
- a human-derived protein consisting of the full-length amino acid sequence described in SEQ ID NOs: 2, 4 and 6, a combination of SP-B and SP-C, and a combination of SP-B and SP-C1 , Can be used respectively.
- Mutated fragments and the like can also be used.
- Mutants or synthetic analogs in which at least one amino acid has been substituted and / or deleted can be used.
- amino acid numbers are indicated by Met occupying the N-terminus of each sequence as the first amino acid, and in the order of the C-terminal direction (from left to right of the described sequence) in the order ⁇ : .
- SEQ ID NO: 7 amino acid sequence of positions 214 to 225 of SEQ ID NO: 2 (SP-B fragment);
- SEQ ID NO: 8 amino acid sequence of positions 257 to 266 of SEQ ID NO: 2 (fragment of SP-B);
- SEQ ID NO: 9 Amino acid sequence of Nos. 29 to 58 of SEQ ID NOS: 4 and 6 (SP-C fragment)
- SEQ ID NO: 10 Amino acid sequence of Nos.
- SEQ ID NO: 11 SEQ ID NO: 102 to 110 amino acid sequence (SP-B fragment); SEQ ID NO: 12: SEQ ID NO: 119 to 127 amino acid sequence (SP-B fragment); SEQ ID NO: 13: SEQ ID NO: SEQ ID NO: SEQ ID NO: 14 amino acid sequence at positions 136 to 142 (SP-B fragment); SEQ ID NO: 14 amino acid sequence at positions 171 to 185 of SEQ ID NO: 2 (SP-B fragment); SEQ ID NO: 15 amino acid sequence at positions 201 to 279 of SEQ ID NO: 2 SEQ ID NO: 16 amino acid sequence (SP-B fragment); SEQ ID NO: 16 SEQ ID NO: 2 amino acids 253 to 278 (SP-B fragment); SEQ ID NO: 17 SEQ ID NO: 300 to 307 amino acids Sequence (SP-B fragment); SEQ ID NO: 18 Amino acid sequence at positions 317 to 330 of SEQ ID NO: 2 (SP-B fragment); SEQ ID NO: 19 Am
- SEQ ID NO: 2 SEQ ID NO: 14: Amino acid sequence of Nos. 24-58 of SEQ ID NO: 4 and 6 (SP-C fragment)
- SEQ ID NO: 21 Amino acid sequence of Nos. 24-58 of SEQ ID NO: 4 and 6 (SP-C fragment)
- an amino acid sequence represented by SEQ ID NO: 2, 7, 8, 10-20 And at least L species selected from the group consisting of SP-B and fragments thereof, and SP-C (and SP-C1) and fragments thereof comprising the amino acid sequences of SEQ ID NOs: 4, 6, 9 and 21. At least one selected from them can be used in combination.
- a phospholipid contained in the lung surfactant for example, phosphatidylcholine (lecithin), dipalmitoylphosphatidylcholine, phosphatidylserine and the like.
- dipalmitoyl glycerol phosphocholine diasylglycerol phosphoglycerol, phosphatidyl reglycerol (cardio lipin), dilauroyl phosphatidyl glycerol, dimyristoyl phosphatidyl glycerol, dipalmitoyl phosphatidyl glycerol, distear yl phosphatidyl glycerol, And phosphatidylethanolamine, phosphatidic acid, sphingomyelin, and the like.
- fatty acid lauric acid, myristic acid, palmitic acid, stearic acid, palmitooleic acid, oleic acid and the like can be used.
- lipids derived from aquatic gait such as whales, tuna, and dolphins with active lung inflation can be used.
- a commercially available pulmonary surfactant containing hydrophobic or lipophilic SP-B and SP-C and a phospholipid has been approved by relevant authorities for its safety and efficacy as a therapeutic agent for RDS
- trade name Surfacten, Infasurf, Curosrf, Humansurf, Exosurf> Alveofact, etc. can be used as AD weekly.
- commercially available preparations containing SP-A and SP-D, which are hydrophilic or water-soluble, after SP-B and SP-C may be, for example, 1-butanol to dissolve these water-soluble proteins. Extract SP-A and SP-D, remove them to below the detection limit, and use them.
- the nasal mucosa can be inflamed without causing inflammation.
- the activated antigen presenting cells, with virus antigen is efficiently incorporated into the cell, without causing induction of IgG production in the mucosal and blood, effective and antiviral I g a production mucosa Preferentially, especially, selectively guided It was.
- influenza virus split antigen which has been conventionally used as a safe inactivated vaccine antigen, includes a complex of a combination of SP-B and SP-C with a phospholipid, or a lipid-soluble region of such a complex.
- a complex of a synthetic peptide of both SP-B and SP-C fragments containing the active region (AD vehicle) with a lipid membrane (AD vehicle) while maintaining the high safety of the split antigen, We have found that split antigen alone achieves selective induction of secretory IgA production with sufficiently enhanced and compensated activation of antigen-presenting cells, which is inferior to live vaccines.
- lung surfactant adsorbs tryptic zegurala, an airway HA processing protease that reduces the influenza virus membrane protein hemadaltinin (HA) to a limited extent and expresses the membrane fusion activity and infectivity of the virus. Inactivation revealed, blocking virus propagation did.
- pulmonary surfactant selectively activates mucosal antigen-presenting cells to activate immune function against viral antigens, and induces secretory IgA, but also induces secretory IgA.
- SP-B and SP-C are important together with lipid components as active ingredients for enhancing mucosal immunity in lung surfactants, and to identify the effective areas of these protein components and the effectiveness of enhancing mucosal immunity Verified.
- the above-mentioned pulmonary surfactant is a physiologically active substance in the living body, and (a) has a property of adsorbing a specific biological substance (Kido H., et al. FEBS Lett. Pulmonary surfactant is a potetitial endogenous inhibitor). of proteolytic activation of Sendai virus and influenza Avirus, 322 (29), 115-119, 1992), (b) secreted from alveolar H-type cells and Clara cells and selectively taken up by macrophages. Metabolism (Akira Fuwabe, J. Jpn. Med. Soc. Biol. Interface; Surfactant metabolism disorders in alveolar proteinosis, 33, 10-13, 2002), and (c) related cells For example, they focused on antigen-presenting cells (dendritic cells) and metabolized them.
- the active ingredient region of B or the mucosal immune-inducing domain was identified as a peptide consisting of the following amino acid sequence:
- SP-B 214-225 Leu lie Lys Arg lie Gin Ala Met lie Pro L s Gly (SEQ ID NO: 7);
- SP-B 257-266 Leu Leu Asp Thr Leu Leu Gly Arg Met Leu (SEQ ID NO: 8).
- SP-C 29-58 Cys Pro Val His Leu Lys Arg Leu Leu He Val Val Val Val Val Leu lie Val Val Val lie Val Gly Ala Leu Leu Met Gly Leu (distribution number 9).
- a component of the pulmonary surfactant induces an increase in the expression of MHC Class II, CD40, and B7-2 in antigen-presenting dendritic cells, causing T-lymphocytes.
- TGF- ⁇ ⁇ ⁇ ⁇ induces local force in the mucosa to promote class switching to IgA-producing B-lymphocytes. .
- the first purpose is to establish a mucosal immunization method.
- AD Vehicle By providing and utilizing the AD Vehicle, we will achieve 31-selective induction of the production of antigen-specific IgA, which is an effective substance for mucosal immunity, as well as safely and effectively (with no side effects) mucosal immunity induction and methods.
- the second objective is to improve the quality of AD vehicles in terms of safety, efficacy and homogeneity by using synthetic peptides.
- Synthetic peptide of SP-B mucosal immunity inducing activity domain comprising the amino acid sequences of SP-B 214-225 and SP-B 257-266 described above
- SP-C mucosal immunity inducing domain A synthetic peptide (consisting of the amino acid sequence of SP-C 29-58), a synthetic analog thereof, a long-chain synthetic peptide containing such an amino acid sequence as a part thereof, and a lung surfactant lipid.
- a complex (AD vehicle) prepared with the component to improve the quality of the AD vehicle.
- the third purpose is to replace conventional subcutaneous vaccination of vaccine with transmucosal administration.
- AD vehicle as inactivated vaccine for respiratory tract infection virus, for example, inactivated vaccine for influenza, SARS, measles, rubella, mumbus, etc., and also for inactivated vaccine for intestinal sensation ⁇ virus, for example, inactivated vaccine for rota, polio, etc. And these skins Convert the inoculated vaccine to a mucosal vaccine.
- the fourth objective is to use AD vehicles in inactivated vaccines against viral infections via mucous membranes other than the respiratory tract and intestinal tract, such as AIDS, inactivated vaccines such as hepatitis I and hepatitis C. It is to provide.
- the fifth object is to provide a method that can use an AD vehicle for DNA vaccine, live vaccine, prevention and treatment of allergy, and the like.
- a sixth object is to provide a method of using an AD vehicle in percutaneous inoculation (application, application, etc.) as an immune route capable of inducing IgA other than mucosa.
- the seventh objective is to open the way for the use and application of AD Vik not only in DDS and pharmaceuticals but also in agriculture and fisheries.
- the AD vehicle proposed by the present invention differs in performance and action from the adjuvant conventionally used in immunology as follows. That is, conventional adjuvants are usually inoculated subcutaneously or intramuscularly, and cause a local inflammatory reaction, attract antigen-presenting cells ⁇ B- and T-lymphocytes, and use a foreign substance that exerts the ability as an active ingredient. In addition, mineral oils and metal salts that induce sustained release and retention of antigens are used in combination to maintain a prolonged inflammatory response, and are known as conventional mucosal vaccines' adjuvants.
- these substances are foreign substances such as Escherichia coli heat labile toxin and cholera toxin, which may cause harmful effects and side effects, whereas the AD vehicle according to the present invention has a local inflammatory reaction.
- the active ingredient in pulmonary surfactant or its active domain is limited, and Use a low molecular base peptide comprising, thereby realizing an effective mucosal vaccine. Therefore, a very safe, and is non-prone manner. 5.
- the following (1) to (5) are provided, respectively.
- the AD vehicle comprises the following groups I (pulmonary surfactant protein B and natural and synthetic polypeptides derived from or derived from protein B), group I (pulmonary surfactant protein C and At least one substance selected from the group consisting of natural and synthetic polypeptides derived from or caused by the protein C) and the group m (lipids such as phospholipids and fatty acids).
- groups I pulmonary surfactant protein B and natural and synthetic polypeptides derived from or derived from protein B
- group I pulmonary surfactant protein C and At least one substance selected from the group consisting of natural and synthetic polypeptides derived from or caused by the protein C
- the group m lipids such as phospholipids and fatty acids
- Pulmonary surfactant protein B and a polypeptide consisting of the following amino acid sequence described in SEQ ID NO: 2 (The amino acid numbers are as follows: N-terminal Met is the first amino acid; Nos. 1-381 (SEQ ID NO: 2), 214-225 (SEQ ID NO: 7), 257-266 (SEQ ID NO: 8), Nos. 1-20 (SEQ ID NO: 10) Nos. 102-110 (SEQ ID NO: 11), Nos. 119-127 (SEQ ID NO: 12), Nos. 136-142 (SEQ ID NO: 13), Nos. 171-185 (SEQ ID NO: 14), No. 201-279 (SEQ ID NO: 15), No. 253-278 (SEQ ID NO: 16), No.
- the m group is a sheet-like or roll-like lipid membrane, and a plurality of chains of the I group and the ⁇ group are each in a spike shape in a state where a hydrophobic region end is inserted into the lipid membrane. Being planted is one preferred aspect of its configuration and shape.
- a mucosal vaccine obtained by coexisting, contacting, capturing or adsorbing an antigen to the antigen drug vehicle of (1), and inducing mucosal immunity.
- An agent for preventing and treating allergy which is obtained by coexisting, contacting, trapping, or adsorbing an allergen in the antigen drug vehicle of (1), and inducing mucosal immunity. Its effect is, for example, inactivation or desensitization of allergens such as cedar pollen and mites inhaled by the nasal cavity or nasopharyngeal mucosa.
- Transmucosal and / or transdermal DDS obtained by coexisting, contacting, trapping or adsorbing an effective amount of a drug in the antigen drug vehicle of (1).
- the method is characterized in that a mucosal vaccine obtained by coexisting, contacting, capturing or adsorbing an antigen with the antigen drug vehicle of (1) above is administered to the nose or upper respiratory tract.
- a method for inducing mucosal immunity In the above inventions (2), (3) and (5), the induction of mucosal immunity is promoted by the production of IgA antibodies locally in the mucosa, and the TGF- ⁇ and Th2 type This is a preferred mode that is characterized by promoting the production of in.
- Group I pulmonary surfactant protein B and a group of natural and synthetic polypeptides derived from or derived from protein B
- Group I pulmonary surfactant protein C and natural and synthetic polypeptides derived or derived from protein C
- lipids in Group I for example, a mixture of 71 mg of phosphatidylcholine, 21 mg of phosphatidylglycerol, and 4 mg of phosphatidylserine can be employed (total amount of lipids is 96 mg).
- SP-A and D If a commercially available pulmonary surfactant preparation for the treatment of RDS is used, which has been confirmed to contain SP-B and C, the suspension prepared according to the instructions for use is used as is in the antigen drug vehicle solution. Can be used as. (3) Preparation of mucosal vaccine
- the antigen drug vehicle solution to the vaccine stock solution and mix so that the dry weight ratio A / V of the antigen drug vehicle amount (V) to the antigen amount (A) in the vaccine is about 0.2 to about 5.
- the weight ratio A / V l is adopted for 1,000 ml of a vaccine stock solution with an antigen content of 1 pg / ml
- the antigen drug vehicle (100 mg / 5 ml) solution prepared in (2) above will be used.
- the addition volume is 50 ⁇ .
- a homogenizer, a mixer, a shaker, a stirrer, or the like can be used.
- the pulmonary surfactant used as the "antigen drug vehicle (AD vehicle)" was obtained from the bovine lung using the method of Howgood et al. (Howgood S, et al.,: Effects of a surfactant-associated protein and calcium ions on the structure and surface activity). of lung surfactant lipids. Biochemistry 24, 184-190, 1985) or a sample (PSF-1) prepared by biochemistry 24, or, in many cases, extract this sample with 1-butanol to extract the water-soluble protein component SP-A. , SP-D removed or reduced to below detection limit (Haagsman HP, et al., The major lung surfactant protein, SP28-36, is a calcium-dependent, carbohydrate binding protein, J. Biol. Chem.
- PSF-2 contains at least 40% by weight of phospholipids composed mainly of phosphatidylcholine dipalmitoyl phosphatidylcholine, and 10-20% of phosphatidylglycerol and 2-5% of phosphatidylserine, similar to lung surfactant lipids.
- a preparation containing 0 to 3.5% of either or both of the synthetic peptides in the effective region of the soluble protein SP-B and SP-C is used.
- PSF-5 was also studied.
- a known product corresponding to PSF-1, PSF-2 for example, trade name Surfacten, Infasurf, cue mouth safety
- mice and 10-week-old Hartley guinea pigs were purchased from Nippon S.L.C., Inc. (Shizuoka, Japan) and used. All animal experiments were conducted in the infected animal zoo (P2 level) at the Experimental Animal Center, Tokushima University School of Medicine, and were conducted according to the guidelines of the Animal Experiment Committee of the University of Tokushima School of Medicine.
- Influenza virus A Aichi / 68/2 / H3N2 strain-inoculated suspension from embryonated chicken eggs (1 x 108 Plaque forming unit (PFU)) (Provided by Prof. Masanobu Ouchi, Department of Microbiology, Kawasaki Medical University) The following procedure was used to create a split influenza vaccine.
- ⁇ -Propiolactone (Wako Pure Chemical Industries, Ltd. Japan 'Osaka) was used for a virus suspension dialyzed overnight against 0.004M PBS (Yukara Bio Inc. Japan ⁇ Tokyo-Shiga) to 0.05% of the volume and a final concentration of 8 ⁇ . And incubated for 18 hours in an ice bath.
- ⁇ -propiolactone was hydrolyzed by incubating at 37 ° C for 1.5 hours. After that, the final concentration becomes 0.1%. Then, Tween20 (Wako Pure Chemical Industries, Ltd.) was added, and then an equivalent amount of Tween and Jechiru-Tele (Wako Pure Chemical Industries, Ltd.) were added. The aqueous layer was collected by centrifuging this solution at 2000 rpm for 5 minutes. Furthermore, getyl ether was removed from the water layer using the Automatic Environmental SpeedVac System (SAVANT INSTRUMENTS, INC., New York, USA). This was filtered through a Millex 0.45 ⁇ filter (MILLIPORE Mass., USA) and used as an inactivated split influenza vaccine.
- SAVANT INSTRUMENTS Automatic Environmental SpeedVac System
- the split-type influenza vaccine produced by the above-mentioned production method was used as an “AD vehicle” for the lung surfactant (PSF-1), 1-butanol-extracted lung surfactant (PSF-2), and SP-B.
- SP-C effective region synthetic peptide and pulmonary surfactant lipids PSF-3,4,5
- known pulmonary surfactant products or cholera toxin B subunit (CTB, SIGMA America, (Missouri) was used as a mixture.
- Pulmonary surfactant or the above equivalent was suspended in PBS at the concentration required for vaccine administration before use, and sonicated at room temperature for 5 minutes to obtain a uniform suspension.
- the above-prepared preparation was diluted with PBS to a solution equivalent to 0.1 pg / l ⁇ ⁇ dry weight of Phosphate buffered saline (PBS), and this was diluted 1 ⁇ per animal per side.
- PBS Phosphate buffered saline
- the split-type influenza vaccine was diluted with PBS to a 0.1 g / 50 ⁇ 50 solution, and administered subcutaneously to the neck of the mouse.
- the control group contains the vaccine solution The same amount of PBS was administered.
- mice The vaccinated mice were subjected to laparotomy and thoracotomy under ventalpital anesthesia, the trachea was incised, 3 Fr with an Atom vein catheter node (Atom Medical Co., Ltd., Tokyo, Japan) was inserted into the lungs, and 1 ml of saline was injected. This liquid was recovered. This was repeated three times, and a solution collected, ff 13 ml, was used as an alveolar lavage solution. After collecting the lung lavage fluid, an atom venous catheter was inserted into the nasal cavity from the incised trachea, 1 ml of physiological saline was injected, and the fluid coming out of the nose was collected. This solution was used as a nasal washing solution. Further, blood was collected from the heart, and serum was prepared by centrifugation at 5,000 rpm for 10 minutes.
- Atom vein catheter node Atom Medical Co., Ltd., Tokyo, Japan
- the protein content of nasal washes, lung washes, and serum was measured using the BCA Protein Assay Reagent Kit (PIERCE, Illinois, USA) (Smith PK. Et al.,: Measurement of protein using bicmchonmic acid. Anal. Biochem., 150, 76-85, 1985).
- the absorbance at 562 nm was measured using SPECTRAmax PLUS 384 (Molecular Devices Corporation, USA, California).
- the same influenza virus strain, A Aichi / 68/2 / H3N2 strain, used for the preparation of the split influenza vaccine was used for infection.
- Two weeks after the completion of the second immunization the mice were anesthetized with a ether, and the suspension from the influenza virus-developed chicken eggs was instilled in both nasal cavities with a total of 7 ⁇ 10 4 PFU / 3 ⁇ .
- Three days after infection, nasal cavity and alveolar lavage fluid were prepared as described above and used for evaluation of virus infectivity. Evaluation of virus infectivity was performed using ⁇ 549 cells (provided by Dr. Masanobu Ouchi, Kawasaki Medical University, Department of Microbiology).
- ⁇ 549 cells were cultured under the conditions of 5% fetal calf serum / DMEM (Gibco Ameri New York). ⁇ 549 cells ⁇ The cells were subcultured on a culture plate (Gleiner-Stuttgart, Germany) so that they became 100% confluent. After 24 hours, the medium was replaced with a serum-free medium. Nasal-alveolar lavage fluid of influenza infected mice each ⁇ E Le dropwise by 500 ⁇ , and culture was performed at 16 hours 37 12 hours C0 2 incubator scratch. A 1% PBS solution of red blood cells collected from a guinea pig was added thereto, and the mixture was allowed to stand at room temperature for 5 minutes.
- the cells were washed with 1 mM Ca2 ⁇ / Mg2 ⁇ PBS, and the cells in which erythrocytes were agglutinated were counted as virus-infected cells, and the virus infectivity was evaluated (Tashiro M., Homma ⁇ : Pne motropism of Sendai virus in relation to protease-mediated activation in mouse lungs. Infect. Immun. 39, 879-888, 1983).
- IgG fraction was purified from the lung lavage of the influenza vaccine-administered and virus-infected mice by affinity chromatography using a recombinant E. coli-expressed ProteinG Sepharose 4B column (ZYMED LABORTORIES INC, San Francisco, USA).
- Anti-mouse IgA goat IgG (SIGMA) was bound to a BrCN-activated Sepharose 4B column (Amersham Bioscience America's New Zealand), and the IgA fraction was purified by affinity chromatography using the ProteinG flow-through fraction. did.
- the inactivated split influenza vaccine used for immunization was bound to a BrCN-activated Sepharose column, and the antigen was used from the IgA and IgG fractions.
- Anti-influenza-specific IgA and IgG were respectively purified by affinity chromatography.
- the coupling of the split-type influenza protein as a ligand to the column was performed using 0.1 M NaHCO 3 /0.5 M NaCl buffer (pH 8.5), and the free ligand was bound to 0.1 M acetic acid / After removal using a 0.5 M NaCl buffer (pH 8.5), neutralization was performed with PBS (pH 7.5).
- Anti-influenza IgA and IgG contents in the nasal cavity, alveolar lavage fluid and serum were quantified by ELISA assay.
- the ELISA assay was performed according to the method of Mouse ELISA quantitation kit of BETHYL LABORATORIES (Ameriki, Texas).
- 96-well Nunc Immunoplate (Nalgen Nunc International, New York) Add 1 pg of vaccine to each well and 100 ⁇ l of serum serum albumin (BSA, SIGMA America 'Missouri) 1 pg / ml PBS solution to each well, and in 4 The reaction was carried out.
- BSA serum serum albumin
- the vaccine solution was rinsed three times with a washing solution (50 mM Tris, 0.14 M NaCl, 0.05% Tween 20, pH 8.0) to remove the vaccine solution.
- a washing solution 50 mM Tris, 0.14 M NaCl, 0.05% Tween 20, pH 8.0
- 200 ⁇ l of 50 mM Tris-HCl buffer (pH 8.0) containing 0.15 M NaCL 1% BSA was added to each well, and a blocking reaction was performed at room temperature for 1 hour.
- nasal washing solution and lung washing solution diluted appropriately with sample binding buffer (50 mM Tris, 0.15 M NaCl, 1% BSA, 0.05% Tween 20, pH 8.0)
- sample binding buffer 50 mM Tris, 0.15 M NaCl, 1% BSA, 0.05% Tween 20, pH 8.0
- 100 ⁇ of serum was added and reacted at room temperature for 2 hours.
- dendritic cells were prepared from the nose, lung, and spleen collected from mice in each group (4 mice per group) using the Gonzalez-Juarrero M method (Gonzalez- Juarrero M, Orme IM .: Characterization of murine lung dendritic cells infected with Mycobacterium tuberculosis.Infect Immun 2001; 69: 1 127-33) Preparation was performed. The preparation of dendritic cells from the nose and its collagenase treatment
- the amount of TGF- ⁇ - secreted from the nasal cavity and alveolar lavage fluid was quantified by ELISA assay.
- the ELISA assay was performed using a TGF- ⁇ II ELISA kit (BIOSOURCE INTERNATIONAL, California) according to the instructions attached to the kit.
- Cytokines (interleukin 4: IL-4, I-5, IL-6, IL-13) secreted from the nasal cavity, alveolar lavage fluid, and spleen lymphocytes, respectively. Quantification was performed using an ELISA kit.
- the PSF-2) 0.1] ig or CTB 0.1 was administered together with the PBS solution as a PBS solution to BALB / c mice in both nose at 1 ⁇ .
- As a subcutaneous injection vaccine the same amount of vaccine as the nasal vaccine alone, or PSF-2 as an AD vehicle, or CTB as an adjuvant was added, and a 50 ⁇ PBS solution was administered subcutaneously to the neck of a BALB / c mouse neck.
- a second immunization was performed in the same manner as the first immunization.
- Anti-influenza specific IgA is selectively produced in the nasal cavity and increased in the lavage fluid by nasally administered split-type influenza vaccine, but the amount of this specific IgA is comparable to that of PSF-2 and CTB. Increased to clear.
- split injection flu vaccine alone Increase specific I g A quantity of nasal in the washing solution by was observed, but the degree was lower than that in nasal administration.
- the immunopotentiating effect of PSF-2 and CTB was not observed in both IgA and IgG production.
- using PSF-1 and PSF-3 instead of PSF-2 has achieved the same effect as PSF-2. Similar phenomena were observed for PSF-4 and -5, but the effect has diminished.
- Intranasal administration (a), subcutaneous injection (b) Effect of PSF-2 and CTB on the production of anti-influenza-specific antibodies (IgA, IgG) in lung lavage fluid by influenza vaccine 0.1 split-influenza vaccine as nasal vaccine was administered alone or together with 0.1 g of PSF-2 as an AD vehicle or CTB 0.1 as an adjuvant, and 1 ⁇ l of the PBS solution was administered to both nostrils of BALB / c mice for a total of 2 ⁇ l.
- the subcutaneous vaccine the same amount of vaccine as the nasal vaccine, PSF-2 and CTB were administered subcutaneously to the neck of BALB / c mouse as a 50 ⁇ PBS solution.
- Intranasal administration (a), subcutaneous injection (b> Effect of PSF-2 and CTB on the production of anti-influenza-specific antibodies (IgA, IgG) in blood by influenza vaccine 0.1 split flu vaccine as nasal vaccine was administered alone or with 0.1 pg of PSF-2 as an AD vehicle, or 0.1 ig of CTB as an adjuvant, and 1 ⁇ ⁇ of BALB / c mice was administered to both nostrils in PBS solution for a total of 2 ⁇ as a subcutaneous injection vaccine.
- IgA, IgG anti-influenza-specific antibodies
- Nasal administration subcutaneous injection (b) nasal influenza vaccine, lung, alone Supuritsuto influenza vaccine 0. 1 mu [delta] as the influence nasal vaccine PSF-2, CTB to the antigen presenting ability of dendritic cells of the spleen Or, together with 0.1 pg of PSF-2 and CTB 0,1, a total of 2 ⁇ was administered to both BALB / c mice as a 1 ⁇ PBS solution.
- Split-type influenza vaccine, PSF-2, and CTB in the same amounts as the nasal vaccine were administered subcutaneously to the neck of BALB / c mice as 50 ⁇ PBS solutions as subcutaneous vaccines.
- mice Two days later, the mice are sacrificed, dendritic cells are prepared from the nose, lung, and spleen, and the cell surface expression levels of MHC class II, CD40, B7-1 (CD80), and B7-2 (CD80) are measured by flow cytometry. did.
- Nasal influenza vaccine administered nasal cavity a alveoli (b> mucosal TGF-pl)
- TGF- ⁇ concentration at which the producing cells are localized is important (Stavnezer, J .: Regulation of antibody production and class switching by TGF-beta. J. Immunol. 155 (4), 1647-1651, 1995). Therefore, the TGF- ⁇ concentration in the nasal cavity (a) and the alveoli (b) under the above conditions was examined.
- TGF- ⁇ concentrations in the nasal cavity and alveolar mucosa were significantly increased in the presence of SPF-2 and CTB in both cases of administration of the split influenza vaccine.
- the degree of increase was not significantly different between SPF-2 and CTB.
- FIGS. 5 (a) and (b) In vivo derived SPF-2 was found to increase the concentration of TGF- ⁇ , which promotes the promotion of IgA-secreting B cell differentiation, as much as the exogenous toxin CTB.
- PSF-1 and PSF-3 instead of PSF-2. Similar phenomena were observed for PSF-4 and -5, but the effect was diminished.
- nasal and alveolar lavage fluids showed a marked increase in influenza antibody IgA (blue circles) in the blood when PSF-2 and vaccine were administered.
- IgG red circle
- Non-Patent Document 4 J. Freek van Iwaarden et al. (Non-Patent Document 4) reported that when macrophages are artificially removed from the lung, SP-B and lipids induce a systemic immune response but do not remove macrophages. Reported that in some cases immunity could not be induced. In addition, in the above literature, the amount of SP-B + lipid required to induce a predecessor immune response is 250-300 ⁇ , which is far from the PSF-2 dose (0.2 “ ⁇ ) of the above example. No mention is made of local mucosal immunity.
- TGF- ⁇ and site force-in IL-4, IL-5, I-6, IL-13
- Figs. 7 (a) to 7 (e) significant increase in secretion of TGF- ⁇ IL-5 and IL-6 was observed in mucosal localization (nasal and lung) after vaccination with PSF-2. However, there was no significant increase in IL-4 and IL-13. On the other hand, no significant increase in any cytokine was observed in the spleen.
- nasal lavage fluid and alveolar lavage fluid significantly increased anti-influenza antibody IgA (blue circles) in blood when PSF-3 and vaccine were administered.
- IgG red circle
- serum serum
- IgG red circle
- IgG blue circle
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Pulmonology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
Abstract
Description
Claims
Priority Applications (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020067020581A KR100992492B1 (ko) | 2004-04-05 | 2005-03-22 | 국소 점막 면역 유도 촉진용 항원약물 비히클, 이것을 사용하는 점막 백신, 알레르기의 예방제 또는 치료제, 약물전달 시스템, 및 점막면역의 유도방법 |
JP2006512040A JP4843792B2 (ja) | 2004-04-05 | 2005-03-22 | 経粘膜及び経皮投与を可能にする抗原薬物ヴィークル、これを用いる粘膜免疫の誘導方法、粘膜ワクチン及びdds |
BRPI0508792-9A BRPI0508792A (pt) | 2004-04-05 | 2005-03-22 | veìculo para fármaco-antìgeno, vacina de mucosa, agente para prevenção ou tratamento de alergia, sistema de liberação de fármaco (dds), método para induzir imunidade de mucosa |
US11/547,650 US8268321B2 (en) | 2004-04-05 | 2005-03-22 | Antigen-drug vehicle enabling transmucosal and transdermal administration, and method of inducing mucosal immunity and mucosal vaccine and DDS using the same |
EP05721586A EP1738765B1 (en) | 2004-04-05 | 2005-03-22 | Antigen-drug vehicle enabling transmucosal and transdermal administration and method of inducing mucosal immunity, mucosal vaccine and dds using the same |
CA2579710A CA2579710C (en) | 2004-04-05 | 2005-03-22 | Antigen-drug vehicle enabling transmucosal and transdermal administration, and method of inducing mucosal immunity and mucosal vaccine and dds using the same |
CN2005800120996A CN1942205B (zh) | 2004-04-05 | 2005-03-22 | 可经粘膜和经皮给予的抗原药物媒介物、使用该媒介物的粘膜免疫的诱导方法、粘膜疫苗和dds |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2004111249 | 2004-04-05 | ||
JP2004-111249 | 2004-04-05 | ||
JP2004125036 | 2004-04-21 | ||
JP2004-125036 | 2004-04-21 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2005097182A1 true WO2005097182A1 (ja) | 2005-10-20 |
Family
ID=35124843
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2005/005659 WO2005097182A1 (ja) | 2004-04-05 | 2005-03-22 | 経粘膜及び経皮投与を可能にする抗原薬物ヴィークル、これを用いる粘膜免疫の誘導方法、粘膜ワクチン及びdds |
Country Status (9)
Country | Link |
---|---|
US (1) | US8268321B2 (ja) |
EP (1) | EP1738765B1 (ja) |
JP (1) | JP4843792B2 (ja) |
KR (1) | KR100992492B1 (ja) |
CN (1) | CN1942205B (ja) |
BR (1) | BRPI0508792A (ja) |
CA (1) | CA2579710C (ja) |
RU (1) | RU2396090C2 (ja) |
WO (1) | WO2005097182A1 (ja) |
Cited By (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2007018152A1 (ja) * | 2005-08-05 | 2007-02-15 | The University Of Tokushima | IgA抗体の選択的産生からIgA及びIgG両抗体産生への切換えを可能にする抗原薬物ビークルとこれを用いる経鼻・粘膜ワクチン |
WO2009123119A1 (ja) | 2008-04-02 | 2009-10-08 | 国立大学法人徳島大学 | 合成ペプチドを含有する抗原薬物ビークルとこれを用いる粘膜ワクチン |
WO2010087771A1 (en) * | 2009-01-30 | 2010-08-05 | Alphabeta Ab | Compound and method for treatment of alzheimer's disease |
WO2010089940A1 (ja) * | 2009-02-05 | 2010-08-12 | 国立大学法人大阪大学 | 粘膜ワクチン |
WO2013031827A1 (ja) | 2011-08-29 | 2013-03-07 | 国立大学法人徳島大学 | Rsv粘膜ワクチン |
US8785391B2 (en) | 2010-06-24 | 2014-07-22 | Alphabeta Ab | Compound and method for treatment of alzheimer's disease and familial dementia |
US9522170B2 (en) | 2011-04-05 | 2016-12-20 | Alphabeta Ab | Methods of screening compounds for the fibril formation of Aβ peptides based on a decreased trimer/monomer ratio of a chaperone protein |
WO2020045155A1 (ja) | 2018-08-30 | 2020-03-05 | 国立大学法人徳島大学 | 免疫寛容誘導剤及びアレルギー性疾患の治療又は予防剤 |
WO2021206103A1 (ja) * | 2020-04-06 | 2021-10-14 | 応用酵素医学研究所株式会社 | 皮下投与型ワクチン |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN107397956A (zh) * | 2017-08-08 | 2017-11-28 | 南开大学 | 一种铜绿假单胞菌外膜蛋白疫苗的制备方法及应用 |
US20210322511A1 (en) * | 2020-04-17 | 2021-10-21 | President And Fellows Of Harvard College | Methods and compositions for treating a respiratory disease |
EP4228691A2 (en) * | 2020-10-16 | 2023-08-23 | Biosuperior Technology, Inc. | Lung treatment compositions |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH069428A (ja) * | 1992-06-24 | 1994-01-18 | Tokyo Tanabe Co Ltd | 気道部ウィルス疾患の予防及び治療剤 |
EP0976403A1 (en) | 1998-07-30 | 2000-02-02 | Stichting Instituut voor Dierhouderij en Diergezondheid (ID-DLO) | Adjuvant comprising pulmonary surfactant |
US20020155151A1 (en) | 1997-02-11 | 2002-10-24 | Franz Enzmann | Transdermal, oral and intravenous preparations of 2,3-dimethoxy-5-methyl-6-decaprenyl-1,4-benzoquinone |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU5527696A (en) * | 1995-03-31 | 1996-10-16 | Children's Hospital Medical Center | Use of surfactants for introducing genetic material into lun g cells |
EP1440084B1 (en) * | 2001-10-24 | 2010-01-06 | University College Cardiff Consultants Ltd. | Sperm factor sequences |
-
2005
- 2005-03-22 WO PCT/JP2005/005659 patent/WO2005097182A1/ja active Application Filing
- 2005-03-22 CN CN2005800120996A patent/CN1942205B/zh not_active Expired - Fee Related
- 2005-03-22 BR BRPI0508792-9A patent/BRPI0508792A/pt not_active Application Discontinuation
- 2005-03-22 KR KR1020067020581A patent/KR100992492B1/ko active IP Right Grant
- 2005-03-22 RU RU2006138182/13A patent/RU2396090C2/ru active
- 2005-03-22 EP EP05721586A patent/EP1738765B1/en active Active
- 2005-03-22 US US11/547,650 patent/US8268321B2/en active Active
- 2005-03-22 CA CA2579710A patent/CA2579710C/en active Active
- 2005-03-22 JP JP2006512040A patent/JP4843792B2/ja active Active
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH069428A (ja) * | 1992-06-24 | 1994-01-18 | Tokyo Tanabe Co Ltd | 気道部ウィルス疾患の予防及び治療剤 |
US20020155151A1 (en) | 1997-02-11 | 2002-10-24 | Franz Enzmann | Transdermal, oral and intravenous preparations of 2,3-dimethoxy-5-methyl-6-decaprenyl-1,4-benzoquinone |
EP0976403A1 (en) | 1998-07-30 | 2000-02-02 | Stichting Instituut voor Dierhouderij en Diergezondheid (ID-DLO) | Adjuvant comprising pulmonary surfactant |
Non-Patent Citations (5)
Title |
---|
AUGUSTO L.A. ET AL: "Cellular Antiendotoxin Activities of Lung Surfactant Protein C in Lipid Vesicles", AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, vol. 168, 2003, pages 335 - 341, XP002989571 * |
AUGUSTO L.A. ET AL: "Interaction of Pulmonary Surfactant Protein C with CD14 and Lipopolysaccharide", INFECTION AND IMMUNITY, vol. 71, no. 1, January 2003 (2003-01-01), pages 61 - 67, XP002989572 * |
SCHRAM V. ET AL: "Non-cooperative effects of lung surfactant proteins on early adsorption to an air/water interface", BIOCHIMICA ET BIOPHYSICA ACTA, vol. 1616, 2003, pages 165 - 173, XP004464814 * |
See also references of EP1738765A4 |
VAN IWAARDEN J.F. ET AL: "Alveolar Macrophages, Surfactant Lipids, and Surfactant Protein B Regulate the Induction of Immune Responses via the Airways", AM. J. RESPIR. CELL MOL. BIOL., vol. 24, 2001, pages 452 - 458, XP002989570 * |
Cited By (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2007018152A1 (ja) * | 2005-08-05 | 2007-02-15 | The University Of Tokushima | IgA抗体の選択的産生からIgA及びIgG両抗体産生への切換えを可能にする抗原薬物ビークルとこれを用いる経鼻・粘膜ワクチン |
EP1930025A1 (en) * | 2005-08-05 | 2008-06-11 | The University of Tokushima | ANTIGEN-AND-DRUG VEHICLE WHICH ENABLES THE CHANGEOVER FROM THE SELECTIVE PRODUCTION OF IgA ANTIBODY TO THE PRODUCTION OF BOTH OF IgA AND IgG ANTIBODIES, AND TRANSNASAL/TRANSMUCOSAL VACCINE USING THE VEHICLE |
EP1930025A4 (en) * | 2005-08-05 | 2008-12-03 | Univ Tokushima | ANTIGEN-AND-ARZNEI VEHICLE FOR ENABLING THE CONVERSION FROM THE SELECTIVE PRODUCTION OF AN IGA ANTIBODY TO THE PRODUCTION OF IGA AND IGG ANTIBODIES AND TRANSNASAL / MUCOSAL VACCINE WITH THIS VEHICLE |
WO2009123119A1 (ja) | 2008-04-02 | 2009-10-08 | 国立大学法人徳島大学 | 合成ペプチドを含有する抗原薬物ビークルとこれを用いる粘膜ワクチン |
US9402883B2 (en) | 2009-01-30 | 2016-08-02 | Alphareta Ab | Compound and method for treatment of Alzheimer's disease |
US8785390B2 (en) | 2009-01-30 | 2014-07-22 | Alphabeta Ab | Methods for treatment of Alzheimer's disease |
WO2010087771A1 (en) * | 2009-01-30 | 2010-08-05 | Alphabeta Ab | Compound and method for treatment of alzheimer's disease |
WO2010089940A1 (ja) * | 2009-02-05 | 2010-08-12 | 国立大学法人大阪大学 | 粘膜ワクチン |
US8785391B2 (en) | 2010-06-24 | 2014-07-22 | Alphabeta Ab | Compound and method for treatment of alzheimer's disease and familial dementia |
US9522170B2 (en) | 2011-04-05 | 2016-12-20 | Alphabeta Ab | Methods of screening compounds for the fibril formation of Aβ peptides based on a decreased trimer/monomer ratio of a chaperone protein |
WO2013031827A1 (ja) | 2011-08-29 | 2013-03-07 | 国立大学法人徳島大学 | Rsv粘膜ワクチン |
US9463236B2 (en) | 2011-08-29 | 2016-10-11 | Tokushima University | RSV mucosal vaccine |
WO2020045155A1 (ja) | 2018-08-30 | 2020-03-05 | 国立大学法人徳島大学 | 免疫寛容誘導剤及びアレルギー性疾患の治療又は予防剤 |
WO2021206103A1 (ja) * | 2020-04-06 | 2021-10-14 | 応用酵素医学研究所株式会社 | 皮下投与型ワクチン |
Also Published As
Publication number | Publication date |
---|---|
CA2579710A1 (en) | 2005-10-20 |
EP1738765A4 (en) | 2008-09-17 |
CN1942205A (zh) | 2007-04-04 |
RU2006138182A (ru) | 2008-05-20 |
EP1738765A1 (en) | 2007-01-03 |
US8268321B2 (en) | 2012-09-18 |
JPWO2005097182A1 (ja) | 2008-02-28 |
KR20070017348A (ko) | 2007-02-09 |
JP4843792B2 (ja) | 2011-12-21 |
RU2396090C2 (ru) | 2010-08-10 |
CN1942205B (zh) | 2012-06-06 |
CA2579710C (en) | 2013-01-08 |
EP1738765B1 (en) | 2011-10-05 |
US20070141073A1 (en) | 2007-06-21 |
KR100992492B1 (ko) | 2010-11-08 |
BRPI0508792A (pt) | 2007-11-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP4843792B2 (ja) | 経粘膜及び経皮投与を可能にする抗原薬物ヴィークル、これを用いる粘膜免疫の誘導方法、粘膜ワクチン及びdds | |
JP5028627B2 (ja) | IgA抗体の選択的産生からIgA及びIgG両抗体産生への切換えを可能にする抗原薬物ビークルとこれを用いる経鼻・粘膜ワクチン | |
KR101998431B1 (ko) | 리포솜 제제 | |
CN111375055B (zh) | 一种2019-nCoV亚单位疫苗组合物及其免疫方法 | |
JP2011190278A (ja) | 粘膜体表面に接触させてワクチン抗原を包含する物質の効果を調節する新規非抗原性粘膜アジュバント処方 | |
KR101638661B1 (ko) | 백신 벡터 및 면역 반응을 강화시키는 방법 | |
RU2570394C2 (ru) | Мукозальная вакцина | |
Macaubas et al. | Respiratory tolerance in the protection against asthma | |
JP4382163B2 (ja) | ターゲッティング分子を用いた免疫応答の増強 | |
JP5473899B2 (ja) | 合成ペプチドを含有する抗原薬物ビークルとこれを用いる粘膜ワクチン | |
US9119803B2 (en) | Carious tooth vaccine and preparation method | |
WO2015186678A1 (ja) | 粘膜ワクチン用アジュバント | |
Kimoto | Development of a safe and effective novel synthetic mucosal adjuvant SF-10 derived from physiological metabolic pathways and function of human pulmonary surfactant | |
JP2001151698A (ja) | インフルエンザワクチン | |
Feliciano Ruiz | Poly (I: C) adjuvanted corn nanoparticle enhances the breadth of inactivated influenza virus vaccine immune response in pigs | |
Zanvit | Adjuvant mucosal immunization of mice against influenza virus | |
Andersson | Novel allergen preparations for use in allergen-specific immunotherapy | |
Neimert Andersson | Novel allergen preparations for use in allergen-specific immunotherapy |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DPEN | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed from 20040101) | ||
WWE | Wipo information: entry into national phase |
Ref document number: 1020067020581 Country of ref document: KR |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2006512040 Country of ref document: JP Ref document number: 5787/DELNP/2006 Country of ref document: IN |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 200580012099.6 Country of ref document: CN |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2005721586 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2006138182 Country of ref document: RU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2007141073 Country of ref document: US Ref document number: 11547650 Country of ref document: US |
|
WWP | Wipo information: published in national office |
Ref document number: 2005721586 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 1020067020581 Country of ref document: KR |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2579710 Country of ref document: CA |
|
WWP | Wipo information: published in national office |
Ref document number: 11547650 Country of ref document: US |
|
ENP | Entry into the national phase |
Ref document number: PI0508792 Country of ref document: BR |